Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $20.28, for a total transaction of $152,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ DNLI opened at $20.01 on Friday. The business’s fifty day moving average price is $19.99. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $28.86. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14.
Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $12.88 million. On average, research analysts anticipate that Denali Therapeutics Inc will post -1.54 EPS for the current year.
Several analysts have recently commented on DNLI shares. HC Wainwright reaffirmed a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th. ValuEngine raised shares of WPP from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th. TheStreet raised shares of SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a report on Thursday, June 13th. Finally, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Denali Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.50.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.